Curated News
By: NewsRamp Editorial Staff
April 15, 2026
Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment
TLDR
- Tonix Pharmaceuticals' TONMYA offers faster absorption and higher bioavailability than existing treatments, potentially capturing market share in fibromyalgia care.
- A peer-reviewed study of 60 volunteers shows TNX-102 SL achieves faster absorption and higher bioavailability than oral cyclobenzaprine for bedtime dosing.
- This new formulation could improve sleep and reduce pain for fibromyalgia patients, enhancing daily functioning and quality of life.
- Tonix's sublingual tablet is the first new fibromyalgia treatment in 15 years, using faster absorption to target nonrestorative sleep.
Impact - Why it Matters
This development matters because fibromyalgia affects millions worldwide, often causing chronic pain, fatigue, and sleep disturbances that significantly impair quality of life. The condition has seen limited treatment advances in recent years, leaving many patients with inadequate options. TONMYA's sublingual formulation offering faster absorption and improved bioavailability could provide more effective symptom management, particularly for nonrestorative sleep—a core fibromyalgia complaint. Beyond immediate patient benefits, Tonix's broader pipeline targeting CNS disorders and immunological conditions addresses multiple areas of high unmet medical need. The company's research into TONMYA for depression and stress disorders, along with programs for rare diseases like Prader-Willi syndrome and transplant rejection prevention, demonstrates a comprehensive approach to challenging medical conditions. For investors and the healthcare community, Tonix represents innovation in biotechnology with potential market impact across several therapeutic areas.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a commercial-stage biotechnology company, has announced a significant milestone with the publication of a peer-reviewed study in Clinical Pharmacology in Drug Development. The research details the steady-state pharmacokinetic properties of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(R). Conducted with 60 healthy volunteers, the study demonstrated that this sublingual formulation achieves faster absorption, earlier peak plasma concentration, and higher dose-normalized bioavailability compared to oral extended-release cyclobenzaprine. These findings support TONMYA's use for long-term bedtime dosing to target nonrestorative sleep in fibromyalgia patients, potentially reducing pain and improving related symptoms. This development is particularly noteworthy as TONMYA represents the first new treatment for fibromyalgia in over 15 years, addressing a condition with high unmet medical need.
Tonix Pharmaceuticals is a fully-integrated company focused on central nervous system (CNS) and immunology treatments. Beyond TONMYA, their commercial infrastructure supports marketed acute migraine products including Zembrace(R) SymTouch(R) and Tosymra(R). The company is actively exploring TONMYA's potential in other areas through Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. It's important to note that while promising, these product development candidates remain investigational new drugs or biologics whose efficacy and safety have not been established for any indication.
This news was disseminated through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on innovative small-cap and mid-cap companies. TinyGems provides comprehensive corporate communications solutions including access to wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution through IBN's extensive network. The platform aims to deliver unparalleled recognition and brand awareness for companies seeking to reach investors, influencers, consumers, and journalists. For those interested in following developments from companies like Tonix Pharmaceuticals, TinyGems offers SMS alerts by texting "Gems" to 888-902-4192 (U.S. mobile phones only). Additional information and disclaimers are available on the TinyGems website.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharma's TONMYA Study Shows Faster Absorption for Fibromyalgia Treatment
